Hyperfine (HYPR) AI Stock Analysis

• Market Cap: $102.16M
• Dividend Yield: N/A
• Average Volume (3M): 762.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: -9.59%
• EPS Growth: 8.78%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.12
• Shares Outstanding: 63,525,715
• 10 Day Avg. Volume: 1,646,855
• 30 Day Avg. Volume: 762,741
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: 2.86
• Enterprise Value/Gross Profit: 6.24
• Enterprise Value/Ebitda: -0.74
• 1Y Price Target: $1.70
• Price Target Upside: 32.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 53 Neutral
• Price Target: $1.50 ▲(17.19% Upside)

Hyperfine's overall stock score is driven by strong revenue growth and strategic advancements, as highlighted in the earnings call. However, significant profitability challenges and a negative valuation score due to ongoing losses weigh down the overall score. The technical analysis provides a neutral outlook, with no strong momentum indicators.

Positive Factors

Revenue Growth

The consistent revenue growth indicates a strong market demand for Hyperfine's products, enhancing its long-term market position and potential for future profitability.

FDA and International Approvals

FDA and international approvals for new technologies expand Hyperfine's market access and credibility, supporting long-term growth and competitive advantage.

Strong Balance Sheet

A strong balance sheet with no debt provides financial stability and flexibility, allowing Hyperfine to invest in growth opportunities without financial strain.

Negative Factors

Profitability Challenges

Ongoing net losses highlight significant profitability challenges, which could hinder long-term sustainability and require operational improvements.

Negative Cash Flow

Negative cash flow poses a risk to Hyperfine's financial health, potentially limiting its ability to fund operations and invest in future growth.

Delayed Deals

Delays in closing deals can impact revenue forecasts and indicate potential challenges in execution or market conditions, affecting future financial performance.

Hyperfine Business Overview & Revenue Model

Company Description

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

How the Company Makes Money

Hyperfine generates revenue through the sale and leasing of its Swoop Portable MRI systems to hospitals, clinics, and healthcare providers. The company also earns income from the provision of maintenance, support services, and software updates for its imaging systems. Additionally, Hyperfine has established partnerships with healthcare institutions and organizations that contribute to its credibility and market reach, as well as collaborations that may yield further revenue opportunities through research and development initiatives.

Hyperfine Financial Statement Overview

Summary

Hyperfine shows strong revenue growth and a solid equity position with no debt. However, persistent net losses and negative cash flows highlight significant profitability challenges. The high equity ratio and lack of debt provide stability, but the negative ROE and cash flow issues indicate a need for improved operational efficiency.

Income Statement

Hyperfine's income statement shows significant revenue growth over the years, with the latest revenue of $12.89 million compared to $0.29 million in 2020. However, the company continues to operate at a loss, with a net loss of $40.72 million for 2024. The gross profit margin has improved to 45.7% in 2024 from a negative margin in earlier years, but net profit margins remain substantially negative. The EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges. The revenue growth is a positive sign, but the persistent losses are a major concern.

Balance Sheet

The balance sheet of Hyperfine shows a relatively strong equity position with stockholders' equity at $49.04 million by the end of 2024. The company has no debt, resulting in a debt-to-equity ratio of 0, which is a positive aspect. However, the return on equity is negative due to significant net losses. The equity ratio stands at 83.2%, indicating a strong capital structure. The absence of debt and a high equity ratio are strengths, yet the negative ROE reflects profitability challenges.

Cash Flow

Hyperfine's cash flow statement reveals negative free cash flow, with a free cash flow of -$39.15 million in 2024. Operating cash flow exceeds net income, suggesting decent cash conversion efficiency, but both metrics are negative. The company has been investing less over time, which may impact future growth prospects. While the company has managed to finance operations without debt, the continuous negative cash flows pose a risk to long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.80M	12.89M	11.03M	6.81M	1.50M	294.00K
Gross Profit	4.95M	5.89M	4.76M	907.00K	-1.17M	-477.00K
EBITDA	-41.50M	-42.22M	-47.06M	-72.86M	-64.14M	-23.20M
Net Income	-39.36M	-40.72M	-44.24M	-73.16M	-64.83M	-23.36M
Balance Sheet
Total Assets	45.23M	58.90M	94.20M	134.05M	202.47M	71.53M
Cash, Cash Equivalents and Short-Term Investments	25.42M	37.65M	75.18M	117.47M	188.50M	62.68M
Total Debt	250.00K	269.00K	185.00K	0.00	0.00	178.00K
Total Liabilities	10.11M	9.86M	9.80M	10.33M	16.25M	132.58M
Stockholders Equity	35.13M	49.04M	84.40M	123.72M	186.23M	-61.05M
Cash Flow
Free Cash Flow	-35.19M	-39.15M	-42.61M	-72.92M	-49.89M	-23.09M
Operating Cash Flow	-34.03M	-38.77M	-41.81M	-72.34M	-47.18M	-21.52M
Investing Cash Flow	-1.16M	-383.00K	-804.00K	-585.00K	-2.71M	-1.57M
Financing Cash Flow	6.96M	1.02M	174.00K	7.00K	176.77M	60.94M

Hyperfine Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.28
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Neutral. The current price of 1.28 is below the 20-day moving average (MA) of 1.58, below the 50-day MA of 1.43, and above the 200-day MA of 1.02, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 42.49 is Neutral, neither overbought nor oversold. The STOCH value of 5.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HYPR.

Hyperfine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	64 Neutral	$97.17M	12.60	4.92%	―	1.43%	-20.12%
HYPR	53 Neutral	$102.16M	―	-77.26%	―	-9.59%	8.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VVOS	44 Neutral	$21.76M	―	-262.03%	―	2.65%	70.21%
ICCM	40 Underperform	$55.33M	―	-230.80%	―	-16.46%	4.14%
RBOT	39 Underperform	$39.94M	―	-125.63%	―	―	6.48%

Hyperfine Corporate Events

Hyperfine Announces Underwriting Agreement for Stock Offering

On October 15, 2025, Hyperfine, Inc. entered into an underwriting agreement with Lake Street Capital Markets, LLC, to issue and sell 14,000,000 shares of Class A common stock at $1.25 per share, expecting gross proceeds of approximately $17.5 million. The offering, set to close around October 17, 2025, aims to support Hyperfine’s working capital and general corporate purposes, including commercial, manufacturing, and R&D activities, potentially impacting its operational capabilities and market positioning.

The most recent analyst rating on (HYPR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.

Hyperfine Reports Strong Q3 2025 Revenue Growth

On October 15, 2025, Hyperfine, Inc. announced preliminary, unaudited financial results for the third quarter of 2025, highlighting strong business momentum following the launch of its next-generation Swoop® system. The company reported a 27% sequential revenue growth to approximately $3.4 million and a 36% increase in the average device selling price. The successful commercial rollout of the Swoop® system and Optive AI™ software has led to significant traction in the U.S. hospital pipeline, with new placements across critical care and emergency departments. This expansion signals a promising outlook for Hyperfine’s market positioning and stakeholder interests.

The most recent analyst rating on (HYPR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.

Hyperfine Inc. Reports Strong Growth Amid Strategic Advances

The latest earnings call from Hyperfine Inc. painted a positive picture of the company’s trajectory, underscoring strong revenue growth and strategic advancements. Despite facing a net loss and some deal delays, the overall sentiment was optimistic, driven by significant achievements such as FDA clearances and the launch of their next-generation Swoop system. The company’s expanding international presence and margin improvements further contribute to a favorable outlook.

Hyperfine Inc. Navigates Trade Tariff Challenges Amid Global Market Uncertainty

Hyperfine Inc. faces significant business risks due to international trade disputes, particularly involving U.S. trade tariffs and retaliatory measures. Changes in U.S. trade policy could lead to increased tariffs on imported goods, raising costs for essential materials and components. This situation may force the company to adjust prices, affecting product affordability and competitiveness. Retaliatory tariffs could also hinder supply deliveries and limit growth in international markets, potentially impacting Hyperfine Inc.’s financial performance and growth prospects if not effectively managed.

Hyperfine, Inc. Reports Strong Q2 2025 Growth

Hyperfine, Inc. is a pioneering health technology company that has transformed brain imaging with its FDA-cleared, AI-powered portable magnetic resonance imaging system, the Swoop® system, making advanced imaging more accessible in the healthcare sector.

Hyperfine Regains Nasdaq Compliance with Bid Price

On April 30, 2025, Hyperfine, Inc. was notified by Nasdaq that its Class A common stock had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days. However, by August 6, 2025, Hyperfine regained compliance with the Nasdaq’s bid price requirement, thus resolving the issue.

The most recent analyst rating on (HYPR) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.